In addition, it was reported that IL-22 is produced by recipient ILC3s, which can persist after bone marrow transplant (BMT) and protect ICSs from immune-mediated tissue damage by graft versus host disease (GVHD) [100]. This evidence concerns the gene IL22 and graft versus host disease.